3Pop-Busui R, Lu J, Lopes N, et al. Prevalence of diabetic pe- ripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst, 2009,14: 1-13.
4Wiggin TC, Sullivan KA, Pop-Busui R, et al. Elevated tri- glycerides correlate with progression of diabetic neuropathy. Diabetes, 2009,58 : 1634-1640.
5Ansquer JC, Foucher C, Aubonnet P, et al. Fibrates and mi- crovascular complications in diabetes-insight from the FIELD study. Curr Pharm Des, 2009,15:537-552.
6Elliott J, Tesfaye S, Chaturvedi N, et al. Large-fiber dys- function in diabetic peripheral neuropathy is predicted by car- diovascular risk factors. Diabetes Care, 2009,32:1896-1900.
7AI-Ani FS, A1-Nimer MS, Ali FS. Dyslipidemia as a contrib- utory {actor in etiopathogenesis of diabetic neuropathy. Indian J Endocrinol Metab, 2011,15 : 110-114.
8Zhou H, Tan KC, Shiu SW, et al. Increased serum advanced glyeation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant, 2008,23 : 927-933.
9Vaziri ND. Lipotoxicity and impaired high density lipoprotein- mediated reverse cholesterol transport in chronic kidney dis- ease. J Ren Nutr, 2010,20(5 Suppl) ..$35-$43.
10Vincent AM, Hayes JM, Mclean LL, et al. Dyslipidemia-in- duced neuropathy in mice., the role of oxLDL/LOX-1. Diabe- tes, 2009, 58.. 2376-2385.
